The National Health Council held a webinar on the latest developments with biosimilars on Monday, June 12 at 2 p.m. ET. 

Though biosimilar treatments have been utilized in some disease states, like oncology, for some time, growing investment into these products is presenting more opportunity for adoption in the U.S. across broader disease areas. 

This briefing focused on the value biosimilars hold for patient communities and our health care system. An overview of the resources available for increasing the understanding of biosimilars and the role they play in patient health will be provided. The discussion addressed U.S. speed of adoption compared to European counterparts and explore the potential market barriers which can impede access to new treatment options for patients.